Morgan Stanley initiated coverage of ResMed (RMD) with an Overweight rating and A$313 price target The company has a market-leading position in the obstructive sleep apnea market and valuations appear attractive at current levels, with a strong balance sheet position and the highest ROIC across the firm’s Australian Healthcare industry sector coverage, the analyst tells investors.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RMD:
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue